多発性骨髄腫治療薬の世界市場レポート 2024

多発性骨髄腫治療薬の市場規模は、今後数年間で大幅な成長が見込まれています。 2028年には6.2%の年間複合成長率（CAGR）で280億7,000万米ドルに成長すると予想されます。予測期間中に予想される成長は、免疫療法における進行中の革新、標的療法の範囲の拡大、リキッドバイオプシー技術の応用の増加、CAR-T細胞療法の出現、バイオマーカー発見の継続的な進歩に関連しています。予測期間中に予想される注目すべき動向には、長期生存への関心の高まり、エピジェネティック治療の探求、遠隔医療の幅広い役割、新たな治療アプローチへのアクセスの増加、骨髄腫治療における持続可能性の重視の高まりなどが含まれます。

多発性骨髄腫治療薬市場の予想される成長は、血液がんの有病率の増加によって促進されると予想されます。骨髄や免疫系細胞などの造血組織に由来する血液がんには、白血病、リンパ腫、多発性骨髄腫などが含まれます。多発性骨髄腫の治療薬は、がん細胞の増殖を阻害し、細胞分裂を減少させ、さまざまな酵素活性を刺激し、骨の強度を高め、それによって骨の弱体化に伴う痛みを軽減することにより、これらのがんの治療に重要な役割を果たします。 2023年1月の時点で、米国がん協会は、新たに白血病と診断された患者数が約59,610人で、そのうち約20,380人が急性骨髄性白血病（AML）で、白血病による死亡者は23,710人であると報告しました。血液がんの発生率の増加は、多発性骨髄腫治療薬に対する需要の増大を浮き彫りにしています。

バイオテクノロジーと精密医療の進歩は、市場の成長に大きく貢献すると予想されます。革新的な製品を開発するための生物学的システムの応用を含むバイオテクノロジーと、遺伝学や分子プロファイルなどの個人の特性に合わせた個別化されたヘルスケアアプローチである精密医療は、多発性骨髄腫治療薬の活用に役立ちます。これらの高度なテクノロジーは、遺伝的および分子的洞察を活用して、個々の患者に合わせた標的療法を特定し、それによって治療効果を最適化します。 2022年 10月の時点で、Personalized Medicine Coalitionの推定では、75,000を超える遺伝子検査キットと300の個別治療がさまざまながん、遺伝性疾患、慢性疾患に対して利用可能になることが示されています。バイオテクノロジーと精密医療の継続的な進歩は、多発性骨髄腫治療薬市場の拡大の原動力となっています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 マクロ経済シナリオ

• 高インフレが市場に与える影響
• ウクライナ・ロシア戦争が市場に与える影響
• COVID-19による市場への影響

第5章 世界市場規模と成長

• 世界の市場促進要因と抑制要因
  • 市場促進要因
  • 市場抑制要因
• 世界の市場規模実績と成長、2018年～2023年
• 世界の市場規模予測と成長、2023年～2028年、2033年

第6章 市場セグメンテーション

• 世界の多発性骨髄腫治療薬市場、薬剤タイプ別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
• 免疫調節薬
• プロテアソーム阻害剤
• ヒストンデアセチラーゼ阻害剤
• モノクローナル抗体薬
• ステロイド
• 他の種類の薬剤
• 世界の多発性骨髄腫治療薬市場、治療別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
• 標的療法
• 生物学的療法
• 化学療法
• その他の治療法
• 世界の多発性骨髄腫治療薬市場、流通チャネル別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
• 病院薬局
• 小売薬局
• オンライン薬局
• その他の流通チャネル
• 世界の多発性骨髄腫治療薬市場、エンドユーザー別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
• 男性
• 女性

第7章 地域および国の分析

• 世界の多発性骨髄腫治療薬市場、地域別、実績および予測、2018-2023年、2023-2028年、2033年
• 世界の多発性骨髄腫治療薬市場、国別、実績および予測、2018-2023年、2023-2028年、2033年

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 多発性骨髄腫治療薬市場の競合情勢
• 多発性骨髄腫治療薬市場の企業プロファイル
  • Pfizer Inc.
  • Johnson &Johnson Pvt. Ltd
  • Merck &Co. Inc.
  • AbbVie Inc.
  • Bayer AG.

第31章 その他の大手および革新的な企業

• Roche Holding AG
• Novartis AG
• Sanofi SA
• Bristol-Myers Squibb Company
• GlaxoSmithKline Plc
• Takeda Pharmaceutical Company Limited
• Eli Lilly and Company
• Kite Pharma Inc
• Amgen Inc.
• AstraZeneca plc
• Teva Pharmaceutical Industries Ltd.
• Regeneron Pharmaceuticals Inc.
• Daiichi Sankyo Company
• Daiichi Sankyo Co. Ltd.
• Lonza Group AG

第32章 競合ベンチマーキング

第33章 競合ダッシュボード

第34章 主要な合併と買収

第35章 将来の見通しと可能性の分析

第36章 付録

Multiple myeloma pharmaceuticals are medications designed for the treatment of multiple myeloma and related malignancies affecting plasma cells within the bone marrow. These therapeutic agents are specifically formulated to manage skeletal complications associated with myeloma, including pamidronate (Aredia) and zoledronic acid (Zometa).

Key therapeutic categories for multiple myeloma encompass immunomodulatory agents, proteasome inhibitors, histone deacetylase inhibitors, monoclonal antibody therapies, corticosteroids, among others. Targeted therapy represents an innovative approach in oncology, leveraging drugs or compounds to directly engage essential molecular targets pivotal for cancer cell viability and growth. In the context of multiple myeloma, these treatments are tailored to engage specific molecules, such as intracellular proteins, which modulate cellular signaling pathways promoting proliferation. Various therapeutic modalities include targeted therapy, biologic interventions, chemotherapy, among others, with diverse distribution channels encompassing hospital-based pharmacies, community retail pharmacies, online pharmaceutical platforms, and other avenues, catering to both male and female patient demographics.

The multiple myeloma drugs market research report is one of a series of new reports from The Business Research Company that provides multiple myeloma drugs market statistics, including multiple myeloma drugs industry global market size, regional shares, competitors with a multiple myeloma drugs market share, detailed multiple myeloma drugs market segments, market trends and opportunities, and any further data you may need to thrive in the multiple myeloma drugs industry. This multiple myeloma drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The multiple myeloma drugs market size has grown strongly in recent years. It will grow from $20.7 billion in 2023 to $22.09 billion in 2024 at a compound annual growth rate (CAGR) of 6.7%. The growth observed during the historical period can be ascribed to advancements in diagnostic capabilities, successful outcomes in clinical trials, enhanced comprehension of disease biology, improvements in healthcare infrastructure, as well as increased patient advocacy and awareness.

The multiple myeloma drugs market size is expected to see strong growth in the next few years. It will grow to $28.07 billion in 2028 at a compound annual growth rate (CAGR) of 6.2%. The anticipated growth in the forecast period is linked to ongoing innovations in immunotherapy, the expanding reach of targeted therapies, increased applications of liquid biopsy techniques, the emergence of CAR-T cell therapy, and continuous progress in biomarker discovery. Noteworthy trends expected in the forecast period encompass a heightened focus on long-term survivorship, exploration of epigenetic therapies, a broader role for telemedicine, increased accessibility to novel therapeutic approaches, and a growing emphasis on sustainability in myeloma care.

The anticipated growth of the multiple myeloma drugs market is expected to be driven by the increasing prevalence of hematological cancer. Hematological cancers, originating in blood-forming tissues such as bone marrow or immune system cells, include conditions such as leukemia, lymphoma, multiple myeloma, among others. Multiple myeloma medications play a crucial role in treating these cancers by inhibiting the growth of cancer cells, reducing cell division, stimulating various enzymatic activities, and contributing to bone strength, thereby alleviating pain associated with bone weakening. As of January 2023, the American Cancer Society reported approximately 59,610 newly diagnosed cases of leukemia, with around 20,380 cases of acute myeloid leukemia (AML) and 23,710 deaths attributed to leukemia. The rising incidence of hematological cancer underscores the growing demand for multiple myeloma drugs.

The progress in biotechnology and precision medicine is expected to significantly contribute to the market's growth. Biotechnology, involving the application of biological systems to develop innovative products, and precision medicine, a personalized healthcare approach tailored to individual characteristics such as genetics and molecular profile, are instrumental in utilizing multiple myeloma drugs. These advanced technologies leverage genetic and molecular insights to identify targeted therapies personalized for individual patients, thereby optimizing treatment effectiveness. As of October 2022, estimates from the Personalized Medicine Coalition indicated that over 75,000 genetic testing kits and 300 personalized treatments would be available for various cancers, hereditary disorders, and chronic diseases. The continued advancement in biotechnology and precision medicine is a driving force behind the expansion of the multiple myeloma drugs market.

Product innovation is a key trend gaining popularity in the multiple myeloma drugs market. Major companies operating in the multiple myeloma drugs market are focused on developing innovative products to strengthen their Product innovation emerges as a prominent trend shaping the landscape of the multiple myeloma drugs market, with major industry players prioritizing the development of novel products to enhance their market standing and gain a competitive edge. A case in point is Janssen Biotech Inc., a Japanese biotechnology company, which secured approval from the United States Food and Drug Administration in March 2022 for Carvykti, a CAR T-Cell therapy designed for multiple myeloma treatment. Carvykti, utilizing genetically modified autologous T cells, features a chimeric antigen receptor (CAR) targeting B cell maturation antigen (BCMA). Eligible patients, having undergone multiple lines of therapy, including essential myeloma medications, can receive this therapy for the management of relapsed conditions.

Strategic partnerships represent another key approach adopted by major companies in the multiple myeloma drugs market to collaboratively develop and commercialize innovative products. An exemplar is the collaboration between Kite Pharma, a subsidiary of Gilead Sciences Inc., a US-based pharmaceutical company, and Arcellx, a US-based biotechnology company. Their partnership, established in December 2022, focuses on the joint development and commercialization of Arcellx's T-cell therapy, CART-ddBCMA, targeting relapsed or refractory multiple myeloma patients. This therapy incorporates Arcellx's unique D-Domain binder and involves autologous T cells genetically modified for effective multiple myeloma targeting.

In November 2021, Pfizer Inc., a leading pharmaceutical manufacturer headquartered in the United States, successfully completed the acquisition of Trillium Therapeutics for an undisclosed financial amount. This strategic acquisition is part of Pfizer's overarching objective to fortify its oncology portfolio by incorporating cutting-edge and experimental immunotherapies specifically designed for the treatment of hematological cancers. Trillium Therapeutics Inc., the target of the acquisition, is a Canada-based biopharmaceutical company specializing in the development and production of innovative drugs for the treatment of multiple myeloma, a form of hematological cancer.

Major companies operating in the multiple myeloma drugs market report are Pfizer Inc., Johnson & Johnson Pvt. Ltd., Merck & Co. Inc., AbbVie Inc., Bayer AG., Roche Holding AG, Novartis AG, Sanofi S.A., Bristol-Myers Squibb Company, GlaxoSmithKline PLC, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Kite Pharma Inc., Amgen Inc., AstraZeneca PLC, Teva Pharmaceutical Industries Ltd., Regeneron Pharmaceuticals Inc., Daiichi Sankyo Company, Daiichi Sankyo Co. Ltd., Lonza Group AG, Cipla Ltd., ONO Pharmaceutical Co. Ltd., BieGene Ltd., Biotest AG, Onyx Pharmaceuticals Inc., PharmaMar SA, Karyopharm Therapeutics Inc., Poseida Therapeutics Inc., ImmunoGen Inc., Oncopetides AB

North America was the largest region in the multiple myeloma drugs market in 2023. The regions covered in the multiple myeloma drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the multiple myeloma drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The multiple myeloma drugs market consists of revenues earned by entities by providing various therapies such radiation therapy, bone-marrow transplant, surgery and stem-cell transplant. The market value includes the value of related goods sold by the service provider or included within the service offering. The multiple myeloma drug market also includes sales of nuclear export inhibitors, bispecific T cell engager (BiTE), bisphosphonates, and alkylating agents. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Multiple Myeloma Drugs Global Market Report 2024 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on multiple myeloma drugs market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
• Understand how the market has been affected by the coronavirus and how it is responding as the impact of the virus abates.
• Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
• Measure the impact of high global inflation on market growth.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for multiple myeloma drugs ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The multiple myeloma drugs market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The impact of sanctions, supply chain disruptions, and altered demand for goods and services due to the Russian Ukraine war, impacting various macro-economic factors and parameters in the Eastern European region and its subsequent effect on global markets.

The impact of higher inflation in many countries and the resulting spike in interest rates.

The continued but declining impact of covid 19 on supply chains and consumption patterns.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:

• 1) By Drug Type: Immunomodulatory Drugs; Proteasome Inhibitors; Histone Deacetylase Inhibitors; Monoclonal Antibody Drugs; Steroids; Other Drug Types
• 2) By Therapy: Targeted Therapy; Biologic Therapy; Chemotherapy; Other Therapies
• 3) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies; Other Distribution Channels
• 4) By End-User: Men; Women
• Companies Mentioned: Pfizer Inc.; Johnson & Johnson Pvt. Ltd; Merck & Co. Inc.; AbbVie Inc.; Bayer AG.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Multiple Myeloma Drugs Market Characteristics

3. Multiple Myeloma Drugs Market Trends And Strategies

4. Multiple Myeloma Drugs Market - Macro Economic Scenario

• 4.1. Impact Of High Inflation On The Market
• 4.2. Ukraine-Russia War Impact On The Market
• 4.3. COVID-19 Impact On The Market

5. Global Multiple Myeloma Drugs Market Size and Growth

• 5.1. Global Multiple Myeloma Drugs Market Drivers and Restraints
  • 5.1.1. Drivers Of The Market
  • 5.1.2. Restraints Of The Market
• 5.2. Global Multiple Myeloma Drugs Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)
• 5.3. Global Multiple Myeloma Drugs Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)

6. Multiple Myeloma Drugs Market Segmentation

• 6.1. Global Multiple Myeloma Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• Immunomodulatory Drugs
• Proteasome Inhibitors
• Histone Deacetylase Inhibitors
• Monoclonal Antibody Drugs
• Steroids
• Other Drug Types
• 6.2. Global Multiple Myeloma Drugs Market, Segmentation By Therapy, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• Targeted Therapy
• Biologic Therapy
• Chemotherapy
• Other Therapies
• 6.3. Global Multiple Myeloma Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• Other Distribution Channels
• 6.4. Global Multiple Myeloma Drugs Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• Men
• Women

7. Multiple Myeloma Drugs Market Regional And Country Analysis

• 7.1. Global Multiple Myeloma Drugs Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 7.2. Global Multiple Myeloma Drugs Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

8. Asia-Pacific Multiple Myeloma Drugs Market

• 8.1. Asia-Pacific Multiple Myeloma Drugs Market Overview
• Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Multiple Myeloma Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 8.3. Asia-Pacific Multiple Myeloma Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 8.4. Asia-Pacific Multiple Myeloma Drugs Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

9. China Multiple Myeloma Drugs Market

• 9.1. China Multiple Myeloma Drugs Market Overview
• 9.2. China Multiple Myeloma Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
• 9.3. China Multiple Myeloma Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
• 9.4. China Multiple Myeloma Drugs Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

10. India Multiple Myeloma Drugs Market

• 10.1. India Multiple Myeloma Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 10.2. India Multiple Myeloma Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 10.3. India Multiple Myeloma Drugs Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

11. Japan Multiple Myeloma Drugs Market

• 11.1. Japan Multiple Myeloma Drugs Market Overview
• 11.2. Japan Multiple Myeloma Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 11.3. Japan Multiple Myeloma Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 11.4. Japan Multiple Myeloma Drugs Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

12. Australia Multiple Myeloma Drugs Market

• 12.1. Australia Multiple Myeloma Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 12.2. Australia Multiple Myeloma Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 12.3. Australia Multiple Myeloma Drugs Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

13. Indonesia Multiple Myeloma Drugs Market

• 13.1. Indonesia Multiple Myeloma Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 13.2. Indonesia Multiple Myeloma Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 13.3. Indonesia Multiple Myeloma Drugs Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

14. South Korea Multiple Myeloma Drugs Market

• 14.1. South Korea Multiple Myeloma Drugs Market Overview
• 14.2. South Korea Multiple Myeloma Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 14.3. South Korea Multiple Myeloma Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 14.4. South Korea Multiple Myeloma Drugs Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

15. Western Europe Multiple Myeloma Drugs Market

• 15.1. Western Europe Multiple Myeloma Drugs Market Overview
• 15.2. Western Europe Multiple Myeloma Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 15.3. Western Europe Multiple Myeloma Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 15.4. Western Europe Multiple Myeloma Drugs Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

16. UK Multiple Myeloma Drugs Market

• 16.1. UK Multiple Myeloma Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 16.2. UK Multiple Myeloma Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 16.3. UK Multiple Myeloma Drugs Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

17. Germany Multiple Myeloma Drugs Market

• 17.1. Germany Multiple Myeloma Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 17.2. Germany Multiple Myeloma Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 17.3. Germany Multiple Myeloma Drugs Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

18. France Multiple Myeloma Drugs Market

• 18.1. France Multiple Myeloma Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 18.2. France Multiple Myeloma Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 18.3. France Multiple Myeloma Drugs Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

19. Italy Multiple Myeloma Drugs Market

• 19.1. Italy Multiple Myeloma Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 19.2. Italy Multiple Myeloma Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 19.3. Italy Multiple Myeloma Drugs Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

20. Spain Multiple Myeloma Drugs Market

• 20.1. Spain Multiple Myeloma Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 20.2. Spain Multiple Myeloma Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 20.15. Spain Multiple Myeloma Drugs Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

21. Eastern Europe Multiple Myeloma Drugs Market

• 21.1. Eastern Europe Multiple Myeloma Drugs Market Overview
• 21.2. Eastern Europe Multiple Myeloma Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 21.3. Eastern Europe Multiple Myeloma Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 21.4. Eastern Europe Multiple Myeloma Drugs Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

22. Russia Multiple Myeloma Drugs Market

• 22.1. Russia Multiple Myeloma Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 22.2. Russia Multiple Myeloma Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 22.3. Russia Multiple Myeloma Drugs Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

23. North America Multiple Myeloma Drugs Market

• 23.1. North America Multiple Myeloma Drugs Market Overview
• 23.2. North America Multiple Myeloma Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 23.3. North America Multiple Myeloma Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 23.4. North America Multiple Myeloma Drugs Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

24. USA Multiple Myeloma Drugs Market

• 24.1. USA Multiple Myeloma Drugs Market Overview
• 24.2. USA Multiple Myeloma Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 24.3. USA Multiple Myeloma Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 24.4. USA Multiple Myeloma Drugs Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

25. Canada Multiple Myeloma Drugs Market

• 25.1. Canada Multiple Myeloma Drugs Market Overview
• 25.2. Canada Multiple Myeloma Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 25.3. Canada Multiple Myeloma Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 25.4. Canada Multiple Myeloma Drugs Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

26. South America Multiple Myeloma Drugs Market

• 26.1. South America Multiple Myeloma Drugs Market Overview
• 26.2. South America Multiple Myeloma Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 26.3. South America Multiple Myeloma Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 26.4. South America Multiple Myeloma Drugs Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

27. Brazil Multiple Myeloma Drugs Market

• 27.1. Brazil Multiple Myeloma Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 27.2. Brazil Multiple Myeloma Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 27.3. Brazil Multiple Myeloma Drugs Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

28. Middle East Multiple Myeloma Drugs Market

• 28.1. Middle East Multiple Myeloma Drugs Market Overview
• 28.2. Middle East Multiple Myeloma Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 28.3. Middle East Multiple Myeloma Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 28.4. Middle East Multiple Myeloma Drugs Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

29. Africa Multiple Myeloma Drugs Market

• 29.1. Africa Multiple Myeloma Drugs Market Overview
• 29.2. Africa Multiple Myeloma Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 29.3. Africa Multiple Myeloma Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 29.4. Africa Multiple Myeloma Drugs Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

30. Multiple Myeloma Drugs Market Competitive Landscape And Company Profiles

• 30.1. Multiple Myeloma Drugs Market Competitive Landscape
• 30.2. Multiple Myeloma Drugs Market Company Profiles
  • 30.2.1. Pfizer Inc.
    • 30.2.1.1. Overview
    • 30.2.1.2. Products and Services
    • 30.2.1.3. Strategy
    • 30.2.1.4. Financial Performance
  • 30.2.2. Johnson & Johnson Pvt. Ltd
    • 30.2.2.1. Overview
    • 30.2.2.2. Products and Services
    • 30.2.2.3. Strategy
    • 30.2.2.4. Financial Performance
  • 30.2.3. Merck & Co. Inc.
    • 30.2.3.1. Overview
    • 30.2.3.2. Products and Services
    • 30.2.3.3. Strategy
    • 30.2.3.4. Financial Performance
  • 30.2.4. AbbVie Inc.
    • 30.2.4.1. Overview
    • 30.2.4.2. Products and Services
    • 30.2.4.3. Strategy
    • 30.2.4.4. Financial Performance
  • 30.2.5. Bayer AG.
    • 30.2.5.1. Overview
    • 30.2.5.2. Products and Services
    • 30.2.5.3. Strategy
    • 30.2.5.4. Financial Performance

31. Multiple Myeloma Drugs Market Other Major And Innovative Companies

• 31.1. Roche Holding AG
• 31.2. Novartis AG
• 31.3. Sanofi S.A.
• 31.4. Bristol-Myers Squibb Company
• 31.5. GlaxoSmithKline Plc
• 31.6. Takeda Pharmaceutical Company Limited
• 31.7. Eli Lilly and Company
• 31.8. Kite Pharma Inc
• 31.9. Amgen Inc.
• 31.10. AstraZeneca plc
• 31.11. Teva Pharmaceutical Industries Ltd.
• 31.12. Regeneron Pharmaceuticals Inc.
• 31.13. Daiichi Sankyo Company
• 31.14. Daiichi Sankyo Co. Ltd.
• 31.15. Lonza Group AG

32. Global Multiple Myeloma Drugs Market Competitive Benchmarking

33. Global Multiple Myeloma Drugs Market Competitive Dashboard

34. Key Mergers And Acquisitions In The Multiple Myeloma Drugs Market

35. Multiple Myeloma Drugs Market Future Outlook and Potential Analysis

• 35.1 Multiple Myeloma Drugs Market In 2028 - Countries Offering Most New Opportunities
• 35.2 Multiple Myeloma Drugs Market In 2028 - Segments Offering Most New Opportunities
• 35.3 Multiple Myeloma Drugs Market In 2028 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer